LEADER 05226nam 2200601 450 001 9910807753103321 005 20230803220525.0 010 $a1-118-47597-6 010 $a1-118-47594-1 035 $a(CKB)2550000001166758 035 $a(EBL)1574349 035 $a(OCoLC)864747420 035 $a(MiAaPQ)EBC1574349 035 $a(Au-PeEL)EBL1574349 035 $a(CaPaEBR)ebr10814675 035 $a(CaONFJC)MIL548136 035 $a(EXLCZ)992550000001166758 100 $a20131219d2014 uy 0 101 0 $aeng 135 $aur|n|---uuuuu 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aRheumatology board review /$feditor, Karen Law ; associate editor, Aliza Lipson ; cover design by Matt Kuhns 210 1$aHoboken, New Jersey :$cWiley Blackwell,$d2014. 210 4$dİ2014 215 $a1 online resource (ix, 214 pages) $cillustrations (some color) 300 $aDescription based upon print version of record. 311 $a1-118-12791-9 311 $a1-306-16885-6 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aCover; Title page; Copyright page; Contents; List of Contributors; Preface; CHAPTER 1: Non-inflammatory joint and soft tissue disorders; Introduction; Carpal tunnel syndrome; Epidemiology; Pathology; Clinical presentation; Diagnosis; Treatment; Differential diagnosis; Osteoarthritis (OA); Epidemiology; Commonly involved joints; Definition; Risk factors; Pathogenesis; Symptoms; Physical examination; Osteoarthritis treatment; Secondary osteoarthritis; Etiologies; Inflammatory/erosive hand osteoarthritis; Diagnosis; Clinical features; Radiological features; Differential diagnosis for IE-HOA 327 $aTreatmentDiffuse idiopathic skeletal hyperostosis (DISH); Introduction; Clinical findings; Radiologic findings (see also Chapter 11, Review of musculoskeletal radiology); Diagnosis; Differential diagnosis; Treatment; Gout; Causes of early-onset gout; Drugs causing hyperuricemia; Gout treatments; Further reading; CHAPTER 2: Selected topics in rheumatoid arthritis; Introduction; 2010 ACR/EULAR RA classification criteria; Anti-citrullinated antibodies; What are they?; What is the role of ACPA in the diagnosis of RA?; Rheumatoid arthritis and cardiovascular disease 327 $aTreatment advances in rheumatoid arthritisAnakinra - approved 2001; Abatacept - approved 2006; Rituximab - approved 2006; Tocilizumab - approved 2010; Appropriate immunizations and screening in RA patients; Tuberculosis screening; Key points in using vaccines in RA patients; Drug toxicity monitoring; CHAPTER 3: Selected topics in systemic lupus erythematosus: B cells in lupus and lupus nephritis; Introduction; B cell roles in SLE; Therapies targeting B cells; Specific approaches; Existing therapies for SLE; Rituximab; Belimumab 327 $aAdditional therapies targeting B cells in SLE under investigationLupus nephritis; Classification criteria; American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis; CHAPTER 4: Antiphospholipid antibody syndrome; Introduction; Epidemiology; Classification criteria; Clinical criteria; Laboratory criteria; Important considerations stated by the revised Sapporo classification criteria for the APS; The clinical spectrum of APS; aPL antibodies laboratory testing; Lupus anticoagulants (LACs); aCL antibodies and anti-?2GPI antibodies 327 $aLimitations of aPL testingWho should be tested?; Who should not be tested?; Testing individuals on anticoagulant therapy; Treatment; Primary and secondary prevention of thrombosis in individuals with aPL; Management of pregnancy outcomes in women with aPL; CHAPTER 5: IgG4-related disease; Introduction; Histology; Epidemiology; Etiology; Clinical manifestations; Differential diagnosis; Specific organ involvement in IgG4-RD; Head and neck area; Thoracic area; Abdomen and pelvic area; Diagnostic studies; Value of serum IgG4 in the diagnosis of IgG4-RD; Treatment; Prognosis; CHAPTER 6: Myopathies 327 $aIntroduction 330 $aThe field encompassed by rheumatology has evolved rapidly over the last decade to include multiple immune-modulating and biologic medications, new classification criteria, significant updates on bone metabolism, and completely new paradigms of treatment based on groundbreaking studies published within the last 5 years. Although much has been adopted as standard of care based on new data, most textbooks do not reflect these practice changes. Rheumatology Board Review highlights the latest advances in the field and new standards of care, including references to current citations in the medical 606 $aRheumatism$vOutlines, syllabi, etc 606 $aRheumatology$vOutlines, syllabi, etc 615 0$aRheumatism 615 0$aRheumatology 676 $a616.723 701 $aLaw$b Karen$01663032 701 $aLipson$b Aliza$01663033 701 $aKuhns$b Matt$01663029 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910807753103321 996 $aRheumatology board review$94020057 997 $aUNINA